Russian Extreme Hypertriglyceridemia Registry

Hypertriglyceridemia (HTG) is associated with an increased risk of atherosclerotic cardiovascular disease, acute pancreatitis, and all-cause mortality. The risk increases with higher triglyceride levels and is most significant in extreme HTG (triglyceride concentration ≥10 mmol/L). Epidemiological studies in the Russian Federation report a prevalence of extreme HTG of approximately 0.1-0.2% (146,000-292,000 individuals). Extreme HTG can have monogenic or polygenic (multifactorial) origins, which influences the clinical course of the disease.

Written informed consent is obtained from the patient or their legal guardian prior to inclusion.

Data sources include routine diagnostic findings and medical records. Participating sites monitor patients' clinical status as part of routine medical care. There are no interventions in this registry: medications are not changed, no invasive procedures are performed, and no study-specific interventions or procedures associated with additional risk are performed. Only clinical course, laboratory results, lipid profile, and therapeutic measures are documented, including any genetic testing if available.

Patients are followed annually or more frequently if clinically indicated. There is no minimum or maximum age for inclusion, and follow-up duration is not predefined and depends on clinical practice. Participation is voluntary, and patients may withdraw at any time without affecting their medical care. Data are pseudonymized and can be decrypted using a separately maintained key list; data can be deleted upon patient request.

• Major Cardiovascular Events (MACE) [Срок оценки: Baseline and through study completion, an average of 20 years]
• Pancreatitis Recurrences [Срок оценки: Baseline and through study completion, an average of 20 years]
• Pancreatic Necrosis [Срок оценки: Baseline and through study completion, an average of 20 years]
• Low-Density Lipoprotein Cholesterol (LDL-C) [Срок оценки: Baseline and through study completion, an average of 20 years]
• Triglyceride [Срок оценки: Baseline and through study completion, an average of 20 years]
• Total Cholesterol [Срок оценки: Baseline and through study completion, an average of 20 years]
• High-Density Lipoprotein Cholesterol (HDL-C) [Срок оценки: Baseline and through study completion, an average of 20 years]
• Genetic Characterization of Extreme Hypertriglyceridemia [Срок оценки: Baseline (at the time of genetic testing) and during follow-up if additional genetic data become available, through study completion (an average of 20 years).]